PT921789E - Suspensoes liquidas de sabor mascarado - Google Patents

Suspensoes liquidas de sabor mascarado

Info

Publication number
PT921789E
PT921789E PT97917939T PT97917939T PT921789E PT 921789 E PT921789 E PT 921789E PT 97917939 T PT97917939 T PT 97917939T PT 97917939 T PT97917939 T PT 97917939T PT 921789 E PT921789 E PT 921789E
Authority
PT
Portugal
Prior art keywords
polymer
taste
active ingredient
pharmaceutically active
masked
Prior art date
Application number
PT97917939T
Other languages
English (en)
Portuguese (pt)
Inventor
Angelo Mario Morella
Ian Hamilton Pitman
Grant Heinicke
Original Assignee
Faulding F H & Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faulding F H & Co Ltd filed Critical Faulding F H & Co Ltd
Publication of PT921789E publication Critical patent/PT921789E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PT97917939T 1996-05-07 1997-05-07 Suspensoes liquidas de sabor mascarado PT921789E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AUPN9697A AUPN969796A0 (en) 1996-05-07 1996-05-07 Taste masked liquid suspensions

Publications (1)

Publication Number Publication Date
PT921789E true PT921789E (pt) 2004-06-30

Family

ID=3794010

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97917939T PT921789E (pt) 1996-05-07 1997-05-07 Suspensoes liquidas de sabor mascarado

Country Status (11)

Country Link
US (1) US6197348B1 (Direct)
EP (1) EP0921789B1 (Direct)
JP (1) JP4624498B2 (Direct)
AT (1) ATE258432T1 (Direct)
AU (1) AUPN969796A0 (Direct)
CA (1) CA2253811C (Direct)
DE (1) DE69727386T2 (Direct)
DK (1) DK0921789T3 (Direct)
ES (1) ES2215223T3 (Direct)
PT (1) PT921789E (Direct)
WO (1) WO1997041839A1 (Direct)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2754177B1 (fr) * 1996-10-07 1999-08-06 Sanofi Sa Microspheres pharmaceutiques d'acide valproique pour administration orale
DE19809719A1 (de) * 1998-03-06 1999-09-09 Roehm Gmbh Wäßrige Dispersion geeignet zur Herstellung von Überzugs- und Bindemitteln für feste orale Arzneiformen
DE19845358A1 (de) * 1998-10-02 2000-04-06 Roehm Gmbh Überzogene Arzneiformen mit kontrollierter Wirkstoffabgabe
CA2361496C (en) * 1999-02-04 2011-06-07 Abbott Laboratories Ph independent extended release pharmaceutical formulation
EP1064938A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Pharmaceutical dosage forms for controlled release producing at least a timed pulse
IL150294A0 (en) * 1999-12-28 2002-12-01 Ajinomoto Kk Antidiabetic preparation for oral administration
US6617436B2 (en) * 2000-02-29 2003-09-09 Teva Pharmaceutical Industries Ltd. Processes for preparing clarithromycin and clarithromycin intermediate, essentially oxime-free clarithromycin, and pharmaceutical composition comprising the same
FR2826274B1 (fr) * 2001-06-21 2003-09-26 Aventis Pharma Sa Formulation pharmaceutique au gout masque et son procede de preparation
EP1469833B1 (en) 2002-02-01 2021-05-19 Bend Research, Inc. Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus
MXPA04008720A (es) * 2002-03-12 2004-12-06 Squibb Bristol Myers Co Suspension oral de sabor agradable y metodo.
US6930119B2 (en) * 2002-07-17 2005-08-16 Reliant Pharmaceuticals, Inc. Liquid pharmaceutical composition
EP2422772A3 (en) * 2002-09-20 2012-04-18 Alpharma, Inc. Sequestering subunit and related compositions and methods
US20040091544A1 (en) * 2002-11-08 2004-05-13 Ruff Michael D. Coated dibasic calcium phosphate
US20040170686A1 (en) * 2003-01-31 2004-09-02 Fredrickson Jennifer K. Suspension vehicle for coated drug particles
US20040186180A1 (en) 2003-03-21 2004-09-23 Gelotte Cathy K. Non-steroidal anti-inflammatory drug dosing regimen
US20040191326A1 (en) * 2003-03-31 2004-09-30 Reo Joseph P. Taste-masking vehicle for coated oxazolidinone particles
WO2004112866A2 (en) * 2003-06-17 2004-12-29 Filtertek Inc. Fluid handling device and method of making same
CL2004001884A1 (es) * 2003-08-04 2005-06-03 Pfizer Prod Inc Procedimiento de secado por pulverizacion para la formacion de dispersiones solidas amorfas de un farmaco y polimeros.
US20050137262A1 (en) * 2003-12-22 2005-06-23 Hu Patrick C. Highly concentrated pourable aqueous solutions of potassium ibuprofen, their preparation and their uses
US20050163843A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Alprazolam formulations
EP1732513A2 (en) * 2003-12-31 2006-12-20 Alpharma, Inc. Rosiglitazone formulations
US20050191349A1 (en) * 2003-12-31 2005-09-01 Garth Boehm Galantamine formulations
WO2005065673A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Atomoxetine formulations
WO2005065645A2 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Donepezil formulations
EP1841414A1 (en) * 2003-12-31 2007-10-10 Alpharma, Inc. Rosiglitazone and metformin formulations
US20050163858A1 (en) * 2003-12-31 2005-07-28 Garth Boehm Ziprasidone formulations
CA2552114A1 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Solid dosage formulations of galantamine
RU2007106036A (ru) 2004-08-31 2008-10-10 Пфайзер Продактс Инк. (Us) Антитело к cd40: препарат и способы
GB2419094A (en) * 2004-10-12 2006-04-19 Sandoz Ag Pharmaceutical composition of unpleasnt tasing active substances
US7378109B2 (en) * 2004-12-23 2008-05-27 Council Of Scientific And Industrial Research Pharmaceutical composition for improving palatability of drugs and process for preparation thereof
WO2006093784A2 (en) * 2005-02-25 2006-09-08 Mutual Pharmaceutical Company, Inc. Dosage forms of antibiotics and combinations of antibiotics ans symptomatic relief agents
JP2008540437A (ja) * 2005-05-03 2008-11-20 ミユーチユアル・フアーマシユーチカルズ・カンパニー・インコーポレーテツド キニーネを含有する制御放出調合剤
CN1883456B (zh) * 2005-06-20 2010-12-15 常州市第四制药厂有限公司 掩味药物颗粒及其制备方法和用途
JP2007031407A (ja) * 2005-07-29 2007-02-08 Shin Etsu Chem Co Ltd 低置換度セルロースエーテル含有コーティング用組成物及び不快な味が隠蔽されたフィルムコーティング製剤
US20070087056A1 (en) * 2005-08-09 2007-04-19 Claudia Guthmann Pharmaceutical form with sustained pH-independent active ingredient release for active ingredients having strong pH-dependent solubility
US9101160B2 (en) 2005-11-23 2015-08-11 The Coca-Cola Company Condiments with high-potency sweetener
EP1998762B1 (en) * 2006-03-16 2010-11-03 Novartis AG Solid dosage form containing a taste masked active agent
JP4892264B2 (ja) * 2006-03-30 2012-03-07 高田製薬株式会社 リスペリドン水性液剤
ES2600141T3 (es) * 2006-06-19 2017-02-07 Alpharma Pharmaceuticals Llc Composiciones farmacéuticas
US7915247B1 (en) 2006-08-21 2011-03-29 Mutual Pharmaceutical Company, Inc. Methods of use of fenofibric acid
AU2007322269A1 (en) * 2006-10-11 2008-05-29 Alpharma Pharmaceuticals, Llc Pharmaceutical compositions
US8017168B2 (en) 2006-11-02 2011-09-13 The Coca-Cola Company High-potency sweetener composition with rubisco protein, rubiscolin, rubiscolin derivatives, ace inhibitory peptides, and combinations thereof, and compositions sweetened therewith
WO2008065502A1 (en) * 2006-11-29 2008-06-05 Pfizer Products Inc. Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein
TW200835527A (en) * 2006-12-26 2008-09-01 Shionogi & Co Orally disintegrating tablet and bitter taste-masked formulation comprising risperidone
JP4941977B2 (ja) * 2007-04-11 2012-05-30 大蔵製薬株式会社 ベンズイソキサゾール誘導体の経口ゼリー状医薬組成物
WO2008125940A2 (en) * 2007-04-17 2008-10-23 Pfizer Products Inc. Nanoparticles comprising non-crystalline drug
US8309129B2 (en) * 2007-05-03 2012-11-13 Bend Research, Inc. Nanoparticles comprising a drug, ethylcellulose, and a bile salt
US8703204B2 (en) * 2007-05-03 2014-04-22 Bend Research, Inc. Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer
WO2008135852A2 (en) * 2007-05-03 2008-11-13 Pfizer Products Inc. Pharmaceutical compositions comprising nanoparticles and casein
EP2162120B1 (en) * 2007-06-04 2016-05-04 Bend Research, Inc Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
WO2008149230A2 (en) 2007-06-04 2008-12-11 Pfizer Products Inc. Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
US20100215747A1 (en) * 2007-07-13 2010-08-26 Corey Jay Bloom Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers
WO2009073215A1 (en) * 2007-12-06 2009-06-11 Bend Research, Inc. Pharmaceutical compositions comprising nanoparticles and a resuspending material
EP2240162A4 (en) * 2007-12-06 2013-10-09 Bend Res Inc NANOTE PARTICLES WITH A NON-IONIZABLE POLYMER AND AN AMIN-FUNCTIONALIZED METHACRYLATE COPOLYMER
US8623418B2 (en) * 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
CA2709992A1 (en) * 2007-12-17 2009-07-16 Alpharma Pharmaceuticals, Llc Abuse resistant pharmaceutical compositions of opiod agonists
CA2750209C (en) 2009-03-27 2013-07-02 Toray Industries, Inc. Coated solid preparations of valproic acid
US20110150986A1 (en) * 2009-12-18 2011-06-23 Kristin Arnold Quinine formulations, method of making, and metho of use thereof
ES2709766T3 (es) * 2010-03-09 2019-04-17 Alkermes Pharma Ireland Ltd Composiciones farmacéuticas entéricas resistentes al alcohol
WO2013156163A1 (en) 2012-04-19 2013-10-24 Glatt Ag Taste-masked pharmaceutical compositions containing diclofenac
PL2919903T3 (pl) 2012-11-14 2020-12-14 W.R. Grace & Co. - Conn. Kompozycje zawierające materiał biologicznie aktywny i nieuporządkowany tlenek nieorganiczny
WO2017057884A1 (ko) * 2015-09-30 2017-04-06 (주)아모레퍼시픽 자가회복 가능한 코어-쉘 캡슐
US9463183B1 (en) 2015-10-30 2016-10-11 Silvergate Pharmaceuticals, Inc. Lisinopril formulations
WO2020011938A1 (en) 2018-07-11 2020-01-16 Medizinische Universität Wien Glucocorticoids for the topical treatment of autoimmune gastritis
CN113181133A (zh) * 2021-04-25 2021-07-30 海南通用三洋药业有限公司 一种罗红霉素胶囊的制备方法
CN116687843A (zh) * 2022-12-16 2023-09-05 中国人民解放军军事科学院军事医学研究院 一种高稳定性的布瓦西坦溶液及其制备方法和其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE58110B1 (en) * 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5286489A (en) * 1985-08-26 1994-02-15 The Procter & Gamble Company Taste masking compositions
JPS63150220A (ja) * 1986-12-15 1988-06-22 Dainippon Pharmaceut Co Ltd 経口用固形製剤の製造方法
JPS63218247A (ja) * 1987-03-06 1988-09-12 Yoshiaki Kawashima 高機能懸濁液
DE58903964D1 (de) * 1988-11-10 1993-05-06 Ciba Geigy Ag Fluessige orale formulierung.
US5084278A (en) * 1989-06-02 1992-01-28 Nortec Development Associates, Inc. Taste-masked pharmaceutical compositions
IT1246383B (it) * 1990-04-17 1994-11-18 Eurand Int Metodo per il mascheramento del sapore di farmaci
CA2085342A1 (en) * 1990-06-14 1991-12-15 Milton R. Kaplan Stable aqueous drug suspensions
GB9015822D0 (en) * 1990-07-18 1990-09-05 Beecham Group Plc Compositions
CA2068402C (en) * 1991-06-14 1998-09-22 Michael R. Hoy Taste mask coatings for preparation of chewable pharmaceutical tablets
DE4200821A1 (de) * 1992-01-15 1993-07-22 Bayer Ag Geschmacksmaskierte pharmazeutische mittel
JP3265680B2 (ja) * 1992-03-12 2002-03-11 大正製薬株式会社 経口製剤用組成物
WO1993024109A1 (en) * 1992-06-04 1993-12-09 Smithkline Beecham Corporation Palatable pharmaceutical compositions
AU6774694A (en) 1993-04-26 1994-11-21 Affinity Biotech, Inc. Taste-masking pharmaceutical compositions and methods for making the same
ZA945944B (en) 1993-08-13 1996-02-08 Eurand America Inc Procedure for encapsulating nsaids

Also Published As

Publication number Publication date
CA2253811A1 (en) 1997-11-13
US6197348B1 (en) 2001-03-06
ATE258432T1 (de) 2004-02-15
WO1997041839A1 (en) 1997-11-13
EP0921789A1 (en) 1999-06-16
DE69727386T2 (de) 2004-11-11
AUPN969796A0 (en) 1996-05-30
EP0921789B1 (en) 2004-01-28
DK0921789T3 (da) 2004-06-01
JP2000509399A (ja) 2000-07-25
EP0921789A4 (en) 2002-03-13
JP4624498B2 (ja) 2011-02-02
CA2253811C (en) 2006-10-24
ES2215223T3 (es) 2004-10-01
DE69727386D1 (de) 2004-03-04

Similar Documents

Publication Publication Date Title
PT921789E (pt) Suspensoes liquidas de sabor mascarado
CA2089430A1 (en) Aqueous pharmaceutical suspension for pharmaceutical active
CA2019863A1 (en) Aqueous pharmaceutical suspension for substantially water insoluble pharmaceutical actives
ES2085886T3 (es) Composicion farmaceutica de liberacion contenida.
FI970825L (fi) Farmaseuttiset koostumukset, jotka aktiivisen yhdisteen biologisen hyötyosuuden lisäämiseksi sisältävät sappisuolaa ja puskuria
IL99183A0 (en) Water soluble derivatives of taxol,processes for the preparation thereof and pharmaceutical compositions containing the same
WO1995009619A3 (en) Substituted urea and isothiourea derivatives as no synthase inhibitors
ITMI940326A0 (it) Derivati del 3,8-diazabiciclo[3.2.1.]lottano ad attivita' analgesica
EP0680328A1 (en) KETOCONAZOLE COMPOSITIONS FOR LOCAL USE.
FR2766368B1 (fr) Procede de preparation de nanocapsules de type vesiculaire, utilisables notamment comme vecteurs colloidaux de principes actifs pharmaceutiques ou autres
DE69613693D1 (de) 2-heteroarylalkenylderivate der cyclopentano-heptan(heptaen)säure als therapeutisches mittel zur behandlung des erhöhten augeninnendruckes
HRP20020298B1 (hr) Farmaceutske otopine levosimendana
EA199900205A1 (ru) Лекарственные формы для перорального введения, содержащие бета-лактамный антибиотик
NO983464L (no) Buffersystemer for stabilisering av farmas°ytiske preparater
EP0717992A3 (en) Aqueous suspension formulations for pharmaceutical applications
NO904901D0 (no) N-substituerte derivater av 3r,4r-etyl-((1-metyl-1h-imidazol-5-yl)metyl) -2-pyrrolidinon.
NO307048B1 (no) N-metyl-N-[(1S)-1-fenyl-2-((3S)-3-hydroksypyrrolidin-1-yl)- etyl]-2,2-difenylacetamidhydroklorid, legemiddel som inneholder forbindelsen, anvendelse av legemidlet til fremstilling av legemiddelpreparater, farmasøytiske preparater som inneholder l
NO20022828L (no) Nye forgrenede substituerte aminoderivater av 3-amino-1-fenyl- 1H[1,2,4]triazol, fremgangsmåter for deres fremstilling, ogfarmasöytiske preparater inneholdende disse
PL345309A1 (en) Benzofuran derivatives, pharmaceutical composition containing the same, and a process for the preparation of the active ingredient
NO913644D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive aminosyrederivater.
NO20021867D0 (no) Liposomformulering av 6,9-bis-[(2-aminoetyl)- amino]benzo[g]isokinolin-5,10-dion-dimaleat
NO20021527L (no) Pyrimidinderivater, fremgangsmåte for fremstilling av derivatene og legemidler inneholdende de samme som den aktivebestanddel
NO962809D0 (no) Fremgangsmåte for fremstilling av N-substituerte 4-ketoprolinderivater
IS3947A (is) Amínósýru afleiður, aðferð til framleiðslu þeirraog notkunar sem lyfja
FI945414A0 (fi) Menetelmä N,N-disubstituoidun aminofenolin valmistamiseksi